The real-world oral corticosteroid burden in patients starting anti-interleukin-5 therapy
Recruiting
- Conditions
- Severe eosinophilic astma
- Registration Number
- NL-OMON28832
- Lead Sponsor
- Medical Center Leeuwarden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 350
Inclusion Criteria
Included in RAPSODI, receiving anti-IL-5 treatment before 1/1/2019.
Exclusion Criteria
-Inflammatory comorbidities (Rheumatoid disease, inflammatory bowel disease or oncological disease) (based on registration in RAPSODI)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method